Every time a shuttle docks with the International Space Station (ISS), a delicate dance unfolds between the shuttle's docking ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...

To find the best formulation of LNP to bring mRNA into cells, the company teamed up with Dr. Bruno De Geest (Ghent University) because of his expertise in developing LNPs. The eTheRNA research ...

difficile or C. diff. In animal models, this first mRNA-LNP C. difficile vaccine was found to protect against C. difficile ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

BTIG analysts began covering Arcturus Therapeutics (NASDAQ:ARCT) with a positive outlook, assigning a Buy rating and establishing a price target of $41.00. Currently trading at $16.49 with a market ...

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on ...

For instance, mRNA that is packaged using LNP- based vaccine delivery systems enters cells through endocytosis and faces ...